Wellington Partners Venture Capital GmbH

https://www.wellington-partners.com

LinkedIn: https://www.linkedin.com/company/wellington-partners

Wellington Partners is a leading European venture capital firm investing in the most promising early- and growth stage life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling more than €1.2 billion, thereof €590 million committed to life sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in 56 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ), immatics (Nasdaq: IMTX). invendo (acquired by Ambu), MTM Laboratories (acquired by Roche/Ventana), Oxford Immunotec (acquired by PerkinElmer), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), and Themis (acquired by MSD). *

	Start	1998-01-01 established
	Group	Wellington Partners (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Strohmenger, Rainer (Wellington Partners Venture Capital 201303 General Partner)
	Person 2	Hodits, Regina (Wellington Partners 201101– General Partner before part-time advisor before Atlas Venture until 201001)

	Region	München (Munich)
	Country	Germany
	Street	5 Türkenstr.
	City	80333 München
	Tel	+49-89-219941-0
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	1,200,000,000 (fund size (2022) 2022-09-15)

		* Document for »About Section«: Aignostics GmbH. (9/15/22). "Press Release: Aignostics Raises €14m Series A to Advance AI-powered Pathology". Berlin.

		Record changed: 2024-03-30